Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer.

ABSTRACT:

Trial registration

ClinicalTrials.gov Identifier: NCT00203502.

SUBMITTER: Hsu PC 

PROVIDER: S-EPMC7162481 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature